80 companies participated in the K-Cab patent dispute

Largest ever

Following SCD constraints, 247 cases from 80 companies requested a trial on K-Cab's crystalline patent

The patent dispute over HK Innoen's gastroesophageal reflux disease treatment K-Cab has expanded to the largest scale ever.

 

A total of 80 companies challenged HK inno.N.

 

According to the pharmaceutical industry on the 10th, a total of 80 companies have challenged K-Cab crystalline patents by the 9th.

 

On December 24 last year, SCD filed a passive judgment on the scope of rights in the K-Cab crystalline patent for the first time.

 

By the 9th, 80 companies challenged the same patent.

 

These 80 companies qualified for the "first trial request," one of the generic for exclusivity requirements, by filing the same trial within 14 days of the SCD's filing of the trial.

 

It is the largest ever based on a single item.

 

Previously, there were large-scale patent challenges in the pharmaceutical industry, but there were 40 to 50 participating companies.

 

However, Chong Kun-dang and Daewoong Pharmaceutical, which were active in challenging pharmaceutical bio patents, did not enter the dispute.

 

This is because Chong Kun Dang jointly sells HK inno.N and K-Cab.

 

Analysts say that Daewoong Pharmaceutical is selling Fexuclu, a competitive drug of K-Cab.

 

During this period, 247 documents were filed with the Patent Tribunal.

 

The figure adds to all the cases in which a generic company filed a judgment for the purpose of more than two claims.

 

K-Cab is protected by a total of two patents.

 

It is a substance patent that expires in August 2031, and a crystalline patent that expires in March 2036.

 

Among them, the patents requested by generic companies are crystalline patents.

 

If generic companies succeed in avoiding crystalline patents, they will be eligible to release late-stage drugs after the expiration of the substance patent in 2031.

 

Although there is a long time left until the expiration of material patents, the reason why generic companies are interested in patent challenges is that K-Cab is performing very high in the prescription market.

 

According to UBIST, a pharmaceutical market research firm, K-Cab surpassed 100 billion won in prescriptions in 2021, the third year of its launch.

 

Last year, it booked a total of 92.2 billion won in the third quarter, surpassing 100 billion won for the second consecutive year.

 

K-Cab is the flagship product of HK inno.N.

 

It is a P-CAB-based gastroesophageal reflux disease treatment, and continues to grow with advantages such as that it is more effective than existing PPI-based products and can be taken regardless of before and after meals.